VMD

+ Watchlist + Portfolio

Viemed Healthcare, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.94
52-Week Range: $6.05 – $12.61
Market Cap: $326.42M
P/E (TTM): 23.81
EPS (TTM): 0.36
Dividend Yield: —

Advanced Metrics

Price/Book: 2.27
PEG Ratio: —
Return on Equity: 10.45%
Return on Assets: 8.21%
Gross Margin: 57.47%
Operating Margin: 6.48%
Profit Margin: 4.81%
Current Ratio: 1.13
Debt/Equity: 0.08
Total Debt: $11.60M
Free Cash Flow: $28.28M
Revenue Growth: 23.90%
Earnings Growth: -12.40%
Enterprise Value: $343.36M

VMD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$138.83M	$183.01M	$224.26M	$270.28M
Cost of Revenue	$54.15M	$70.22M	$91.05M	$114.82M
Gross Profit	$84.68M	$112.78M	$133.20M	$155.46M
Research & Development	$2.70M	$2.78M	$3.07M	$3.02M
Selling, General & Admin	$73.36M	$93.73M	$112.48M	$130.50M
Operating Expenses	$76.08M	$97.81M	$117.21M	$134.75M
Operating Income	$8.60M	$14.97M	$15.99M	$20.71M
EBITDA	$24.82M	$36.68M	$42.31M	$51.56M
Pretax Income	$8.99M	$14.39M	$16.17M	$21.77M
Income Tax	$2.77M	$4.15M	$4.76M	$6.39M
Net Income	$6.22M	$10.24M	$11.27M	$14.93M
Diluted EPS	0.16	0.25	0.28	0.37
Diluted Shares	39.81M	40.38M	40.81M	40.82M

VMD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$16.91M	$12.84M	$17.54M	$13.50M
Receivables	$15.40M	$18.45M	$24.91M	$25.81M
Inventory	$3.57M	$4.63M	$4.32M	$5.05M
Current Assets	$39.74M	$38.37M	$52.88M	$48.49M
Total Assets	$117.04M	$154.90M	$177.07M	$199.15M
Current Liabilities	$18.86M	$32.12M	$37.33M	$41.06M
Long-Term Debt	—	$6.00M	$3.59M	$11.29M
Total Debt	$694.00K	$10.32M	$6.87M	$15.95M
Total Liabilities	$19.95M	$41.00M	$43.77M	$55.63M
Retained Earnings	$69.85M	$79.50M	$89.69M	$102.89M
Shareholders' Equity	$97.09M	$113.89M	$131.39M	$141.54M
Working Capital	$20.88M	$6.24M	$15.55M	$7.44M

VMD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$27.75M	$45.21M	$39.09M	$51.92M
Capital Expenditure	-$22.90M	-$26.09M	-$37.77M	-$39.98M
Free Cash Flow	$4.85M	$19.12M	$1.32M	$11.93M
Depreciation & Amortisation	$15.63M	$21.86M	$25.37M	$28.61M
Stock-Based Compensation	$5.20M	$5.85M	$6.29M	$9.13M
Investing Cash Flow	-$23.98M	-$52.11M	-$30.70M	-$50.17M
Financing Cash Flow	-$15.27M	$2.83M	-$3.69M	-$5.79M
Share Repurchases	-$9.71M	-$594.00K	-$1.07M	-$14.96M
Net Change in Cash	-$11.49M	-$4.08M	$4.70M	-$4.04M

VMD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$59.13M	$63.06M	$71.91M	$76.18M	$75.41M
Cost of Revenue	$25.85M	$26.32M	$30.57M	$32.08M	$32.59M
Gross Profit	$33.28M	$36.73M	$41.34M	$44.10M	$42.83M
Research & Development	$797.00K	$847.00K	$775.00K	$598.00K	$579.00K
Selling, General & Admin	$30.74M	$31.14M	$34.10M	$34.52M	$37.24M
Operating Expenses	$31.81M	$32.27M	$35.23M	$35.44M	$38.17M
Operating Income	$1.47M	$4.46M	$6.12M	$8.66M	$4.65M
EBITDA	$10.45M	$11.35M	$13.18M	$15.94M	$11.92M
Pretax Income	$3.66M	$4.96M	$5.13M	$8.01M	$3.99M
Income Tax	$952.00K	$1.71M	$1.53M	$2.19M	$1.28M
Net Income	$2.63M	$3.16M	$3.51M	$5.64M	$2.58M
Diluted EPS	0.06	0.08	0.09	0.14	0.06
Diluted Shares	41.63M	41.08M	40.50M	40.16M	40.49M

VMD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$10.16M	$20.02M	$11.12M	$13.50M	$9.76M
Receivables	$26.79M	$26.55M	$29.33M	$25.81M	$31.18M
Inventory	$4.51M	$4.32M	$5.27M	$5.05M	$5.18M
Current Assets	$49.12M	$55.29M	$49.98M	$48.49M	$49.81M
Total Assets	$178.08M	$184.60M	$202.36M	$199.15M	$197.36M
Current Liabilities	$35.49M	$37.27M	$44.19M	$41.06M	$40.71M
Long-Term Debt	$3.53M	$3.46M	$19.59M	$11.29M	$8.33M
Total Debt	$6.76M	$6.89M	$24.70M	$15.95M	$12.44M
Total Liabilities	$41.33M	$42.98M	$66.86M	$55.63M	$51.56M
Retained Earnings	$90.73M	$93.84M	$97.25M	$102.89M	$105.47M
Shareholders' Equity	$134.76M	$139.73M	$133.61M	$141.54M	$143.86M
Working Capital	$13.63M	$18.02M	$5.79M	$7.44M	$9.11M
Net Debt	—	—	$10.02M	—	—

VMD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$2.85M	$12.25M	$18.37M	$18.44M	$8.07M
Capital Expenditure	-$15.48M	-$8.13M	-$7.64M	-$8.74M	-$6.71M
Free Cash Flow	-$12.63M	$4.13M	$10.73M	$9.70M	$1.36M
Depreciation & Amortisation	$6.61M	$6.89M	$7.54M	$7.57M	$7.62M
Stock-Based Compensation	$2.31M	$2.34M	$2.18M	$2.30M	$2.45M
Investing Cash Flow	-$8.53M	-$1.73M	-$32.30M	-$7.61M	-$5.49M
Financing Cash Flow	-$1.70M	-$671.00K	$5.04M	-$8.45M	-$6.33M
Share Repurchases	-$1.58M	-$1.71M	-$11.66M	-$2.00K	-$3.44M
Net Change in Cash	-$7.38M	$9.86M	-$8.89M	$2.38M	-$3.74M

Market Snapshot

About

Viemed Healthcare Inc. provides in-home medical equipment and post-acute respiratory care services to patients with chronic respiratory diseases. The company specializes in ventilators, sleep apnea equipment, and related healthcare services primarily in the United States.